KRBL Q1 FY27 Results (NSE: KRBL)
Signal: Margin expansion
The read
The key inflection is a sharp margin-led earnings acceleration despite revenue falling 5.6% YoY: EBITDA margin expanded to 24.9% from 12.0% in Q1FY26 and PAT rose 73.2% to ₹26074 lakh, but the gross-margin driver is undisclosed and the ED-related qualification remains unresolved.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,495.86 Cr | -5.6% | -1.9% |
| EBIT | ₹348.46 Cr | 71.7% | |
| Net profit | ₹260.74 Cr | 73.2% | |
| EPS | ₹11.39 | 73.1% | |
| EBIT margin | 24.9% |
P&L walk
Revenue declined 5.6% YoY to ₹149586 lakh, but gross margin expanded 940bps to 33.5% and EBITDA margin expanded 1290bps to 24.9%, driving EBITDA up 65.3% and PAT up 73.2%; the margin inflection is not attributed by management in the filing.
Segments
Agri drove the result: revenue declined 4.9% YoY to ₹149187 lakh but segment result rose 86.0% to ₹33492 lakh; Energy revenue rose 9.4% to ₹6535 lakh while its result fell 30.0% to ₹1759 lakh and remained too small to offset Agri's improvement.
Key positives
- EBITDA rose 65.3% YoY to ₹37194 lakh and EBITDA margin expanded 1290bps to 24.9%, the strongest margin level in the recent results series.
- Agri segment result increased 86.0% YoY to ₹33492 lakh despite Agri revenue declining 4.9% to ₹149187 lakh, showing substantial improvement in segment profitability.
- EPS rose 73.1% YoY to ₹11.39, tracking PAT growth of 73.2% without a dilution signal.
- Finance cost fell 45.5% YoY to ₹78 lakh, supporting the conversion of operating profit into PBT.
Key concerns
- Consolidated revenue declined 5.6% YoY to ₹149586 lakh, reversing the 32.1% growth in Q1FY26 and 19.0% growth in Q2FY26.
- Gross margin expanded approximately 940bps even as raw material cost increased to 53.7% of revenue from 44.2% YoY; the filing does not explain the apparent margin tailwind, making sustainability uncertain.
- Energy segment result declined 30.0% YoY to ₹1759 lakh despite 9.4% revenue growth to ₹6535 lakh.
Research and educational content only. Not investment advice.